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Abstract
Background: Transforming growth factor beta 1 (TGF-β1) and platelet-derived growth factor (PDGF) are cytokines
involved in fibrotic processes causing radiotherapy (RT)-induced cardiovascular changes. We aimed to investigate
the associations between TGF-β1 and PDGF and the echocardiographic changes that occur during RT and during
three-year follow-up.
Methods: The study included 63 women receiving adjuvant RT for early-stage breast cancer or ductal carcinoma in
situ. Serum TGF-β1 (ng/ml) and PDGF (ng/ml) levels were measured by enzyme-linked immunoassay and
echocardiographic examination was performed before RT, after RT and at 3 years. Patients were grouped by
biomarker behavior by a trajectory analysis.
Results: TGF-β1 decreased from 19.2 (IQR 17.1–22.3) before RT to 18.8 (14.5–22.0) after RT (p = 0.003) and the
decrease persisted at 17.2 (13.7–21.2) 3 years after RT (p = 0.101). PDGF decreased from 15.4 (12.6–19.1) before
RT to 13.8 (11.7–16.2) after RT, p = 0.001, and persisted at 15.6 (10.4–18.4) at 3 years, p = 0.661. The TGF-β1
level before RT (Spearman’s rho 0.441, p < 0.001) and the three-year change in TGF-β1 (rho = − 0.302, p =
0.018) correlated with global longitudinal strain (GLS) in echocardiography at 3 years.
In trajectory analysis, two TGF-β1 behavior groups were found. Group 1 had significantly higher TGF-β1 levels
before RT, 25.6 (22.3–28.6), than group 2, 17.8 (15.9–19.9), p < 0.001. In multivariable analysis, TGF-β1 trajectory
group 1 (β = 0.27, p = 0.013), left-sided breast cancer (β = 0.39, p = 0.001) and the use of aromatase inhibitors
(β = 0.29, p = 0.011) were significantly associated with a worsening in GLS from before RT to 3 years.
Conclusion: An elevated pretreatment TGF-β1 may predict RT-associated changes in echocardiography.
Keywords: Transforming growth factor beta 1, Platelet-derived growth factor, Cardiotoxicity, Breast cancer,
Radiotherapy, Echocardiography
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Background
Adjuvant radiotherapy (RT) of breast cancer is associ-
ated with an increased risk of cardiovascular morbidity
and mortality [1]. Transforming growth factor beta 1
(TGF-β1) is involved in the process responsible for the
long-term fibrotic effects of RT, including cardiovascular
changes and morbidity [2]. TGF-β1 is produced by plate-
lets, macrophages, fibroblasts, monocytes, and epithelial
and endothelial cells [2]. In a radiation fibrosis model,
the production of profibrotic cytokines, such as TGF-β1
and platelet-derived growth factor (PDGF), is thought to
be induced by radiation, which in turn activates fibro-
blasts. It is suggested that cytokines play an initiative
role, but may not be necessary to maintain the fibrotic
process [2].
TGF-β1 is also released following myocardial injury,
exerting profibrotic actions on the myocardium. This
process is involved in the pathogenesis of different myo-
cardial diseases [3]. Elevated levels of TGF-β1 are also
present in various fibrotic diseases, such as hepatic fibro-
sis, idiopathic pulmonary fibrosis, myelofibrosis or sys-
temic sclerosis [4]. In addition, variation in circulating
TGF-β1 levels is also caused by genetic factors [5]. Muta-
tions in genes determining TGF-β1 levels may be respon-
sible for susceptibility to radiation injury, such as breast
fibrosis or increased cardiovascular morbidity [6, 7].
Only a few studies have examined the effect of adju-
vant breast cancer RT on the circulating levels of TGF-
β1. Two studies have reported that patients who devel-
oped fibrosis of the breast as sequelae of external beam
RT had higher baseline levels of TGF-β1 than those who
did not develop fibrosis [8, 9]. We reported that patients
receiving adjuvant RT for breast cancer with echocardio-
graphic changes from before to after RT had higher
baseline TGF- β1 levels and their TGF-β1 and PDGF
levels decreased during RT [10].
Our aim was to study the behavior of the TGF-β1 and
PDGF levels and their association with the echocardio-
graphic changes from before RT to immediately after
and 3 years after RT.
Materials and methods
Patients
Altogether, 63 patients with available serum samples, re-
ceiving postoperative RT for breast cancer or ductal car-
cinoma in situ (DCIS) were included in this prospective,
observational, single-center study. The included patients
had breast-conserving surgery (n = 62) or a mastectomy
(n = 1) before RT, but none received chemotherapy.
Earlier publication describes the key inclusion and exclu-
sion criteria in detail [11]. The Tampere University hos-
pital ethics committee approved the study (R10160) and
informed consent was obtained from all participants.
Radiotherapy
A detailed description of the RT protocol is found in an
earlier publication [12]. Briefly, the planning target vol-
ume (PTV) received either 50 Gy in 2 Gy fractions or
42.56 Gy in 2.66 Gy fractions. The remaining breast after
breast-conserving surgery or the chest wall after mastec-
tomy with margins constituted the PTV. For the one
patient with axillary node-positive disease, PTV included
the axillary and supraclavicular areas.
Serum biomarker analysis
TGF-β1, PDGF and N-terminal pro-brain natriuretic
peptide (proBNP) were analyzed from serum samples
drawn at the start of RT, at the end of RT and 3 years
after RT. Concentrations of TGF-β1 and PDGF-AB were
measured by enzyme-linked immunosorbent assay with
reagents from R&D Systems Europe Ltd. (Abingdon,
UK). Samples were stored at − 80 °C and all samples
were analyzed simultaneously with reagents from the
same batch. Samples from before and after RT were also
reanalyzed [10]. The detection limit and the interassay
coefficient of variation were 7.8 ng/ml and 5.1% for
TGF-β1 and 3.9 ng/ml and 3.5% for PDGF-AB,
respectively.
Echocardiographic examination
Echocardiographic examination was performed at the
same time points as when the serum samples were
drawn. A single cardiologist (ST) performed all the ex-
aminations by a commercially available ultrasound ma-
chine (Philips iE33 ultrasound system; Philips, Bothell,
WA, USA) and a 1–5MHz matrix-array X5–1 trans-
ducer, as described previously [13, 14].
Statistical analysis
The median and interquartile range (IQR) were calculated
for variables with skewed distributions. The Wilcoxon
signed-rank test was used to test for change in a variable
between measurements before RT, after RT and at 3 years.
The linear relationship between continuous variables was
determined using Spearman’s correlation. The Mann-
Whitney U-test for continuous variables was used to test
for differences in the biomarkers, echocardiographic mea-
surements or radiation doses between two groups. Group
based trajectory modeling was used to determine the two
trajectory groups [15]. The trajectory groups were created
according to the three measurements of TGF-β1 or PDGF
in each patient as a continuous outcome measure and the
groups represent clusters of individuals with similar trajec-
tories and outcomes over time [16]. Models were fitted by
using the flexmix package [17] of the statistical program
R, version 3.3.0, from the R Foundation for Statistical
Computing [18]. The relative goodness of fit was assessed
using Bayesian information criteria (BIC). Fischer’s exact
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test was used to test for differences in categorical variables
in the two trajectory groups. Linear regression was used to
test multivariable associations with the change in GLS
over 3 years. IBM SPSS Statistics software, version 25 for
Windows (Armonk, NY, USA) was used for statistical
testing. P-values under 0.05 were considered statistically
significant.
Results
TGF-β1, PDGF and proBNP
Including all 63 patients, the median TGF-β1 decreased
significantly during RT, p = 0.003 (Table 1). At the
three-year follow-up, the median TGF-β1 level remained
lower than before RT, p = 0.001. The median PDGF also
decreased during RT, p = 0.001. The difference in me-
dian PDGF levels between before RT and at 3 years
remained significant, p = 0.046. The median proBNP
(n = 62) was stable during RT, p = 0.325, but increased
by the three-year follow-up, p < 0.001.
The correlations of TGF-β1 and PDGF at correspond-
ing time points and the changes between these time
points are shown in Table 2. There were significant cor-
relations between the TGF-β1 and PDGF as well as
between the TGF-β1 and proBNP levels (Table 2), but
PDGF and proBNP did not correlate together.
TGF-β1, PDGF and baseline characteristics
Age inversely correlated with the TGF-β1 level at 3 years
(rho = − 0.310, p = 0.013) and the change in TGF-β1
from before RT to 3 years (rho = − 0.280, p = 0.026).
There was no significant correlation between TGF-β1
and body mass index (BMI) or time from surgery to RT.
Furthermore, there was no statistically significant differ-
ence in the TGF-β1 levels before RT in groups with
different comorbidities or the use of medication, e.g.
hypertension, hypothyrosis, coronary artery disease
(CAD), smoking, diabetes and use of aromatase inhibi-
tors (AI), tamoxifen, angiotensin convertase inhibitors
(ACE), acetylsalicylic acid (ASA), or statins.
PDGF at 3 years also inversely correlated with age
(rho = − 0.348, p = 0.005), but not with BMI or time
from surgery to RT. Statin-users had lower median
PDGF levels before RT than did nonusers, 12.0 (10.2–
16.5) ng/ml and 16.5 (13.4–20.4) ng/ml, respectively
(p = 0.024). Furthermore, tamoxifen-users had lower
median PDGF levels after RT than nonusers did, 12.1
(11.6–17.3) ng/ml and 15.6 (12.8–20.1) ng/ml, respect-
ively (p = 0.041). There were no differences in the
median PDGF levels according to the other baseline
characteristics.
TGF-β1 and PDGF levels and echocardiographic
measurements
The TGF-β1 and PDGF levels before RT, after RT, at 3
years, and the changes between these time points correlated
with different structural and functional parameters in echo-
cardiography. Echocardiographic measurements are pre-
sented in Additional file 1: Table S1. The significant
correlations for TGF-β1 and PDGF after RT and at 3 years
and echocardiography are presented in Additional file 2:
Table S2.
Correlations with structural echocardiographic
measurement
The interventricular septum (IVS) (rho 0.256, p = 0.042)
and posterior wall (PW) (rho = 0.318, p = 0.011) thick-
nesses and the left ventricular end systolic diameter
(LVESD) (rho 0.300, p = 0.017) after RT correlated with
TGF-β1 before RT. Additionally, the IVS (rho 0.428, p <
0.001) and PW (rho = 0.389, p = 0.002) thicknesses at 3
years correlated with the TGF-β1 level before RT.
Furthermore, the change in TGF-β1 during RT inversely
correlated with the change in septal calibrated integrated
backscatter (scIBS) during RT (rho =─0.289, p = 0.023).
The change in TGF-β1 from before RT to 3 years inversely
correlated with the change in IVS from before RT to 3
years (rho =─0.255, p = 0.044) and the IVS at 3 years
(rho =─0.383, p = 0.002).
The PDGF level before RT correlated with the change in
IVS from before RT to 3 years (rho = 0.306, p = 0.015). The
PDGF change during RT correlated inversely with the pos-
terior calibrated integrated backscatter (pcIBS) before RT
(rho =─0.341, p = 0.007) and positively with the change in
pcIBS during RT (rho = 0.307, p = 0.016) and the change in
pcIBS from baseline to 3 years (rho = 0.336, p = 0.009). The
PDGF change from before RT to 3 years correlated posi-
tively with the change in left ventricular end diastolic diam-
eter (LVEDD) (rho = 0.267, p = 0.035) and negatively with
the change in IVS (rho =─0.385, p = 0.002) from before
RT to 3 years.
Table 1 TGF-β1, PDGF and proBNP levels in the whole study population
Before RT After RT Three years
n Md IQR Md IQR Md IQR p1 p2 p3
TGF-β1 (ng/ml) 63 19.2 (17.1–22.3) 18.8 (14.5–22.0) 17.2 (13.7–21.2) 0.003 0.001 0.101
PDGF (ng/ml) 63 15.4 (12.6–19.1) 13.8 (11.7–16.2) 15.6 (10.4–18.4) 0.001 0.046 0.661
proBNP (ng/l) 62 75.5 (42.5–125.5) 75.0 (35.5–132.8) 101.0 (55.5–183.3) 0.325 < 0.001 < 0.001
TGF-β1 Transforming growth factor beta 1, PDGF Platelet-derived growth factor, proBNP N-terminal pro-brain natriuretic peptide, RT Radiotherapy, Md Median, IQR
Interquartile range, p1 Change from before to after RT, p2 Change from before to 3 years after RT, p3 Change from after RT to 3 years after RT
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Correlations with systolic echocardiographic measurements
The global longitudinal strain (GLS) at 3 years correlated
positively with the TGF-β1 level before RT (rho 0.441,
p < 0.001) and inversely with the TGF-β1 change during
RT (rho =─0.302, p = 0.018). Furthermore, the GLS
change from before RT to 3 years inversely correlated
with the PDGF level before RT (rho =─0.288, p =
0.022). Likewise, the PDGF change during RT correlated
with the TAPSE change from before RT to 3 years
(rho = 0.262, p = 0.045).
Correlations with measurements of filling pressure and
diastology in echocardiography
The TGF-β1 level before RT inversely correlated with
the mitral early inflow wave velocity (mitral E) (rho
─0.300, p = 0.017) after RT. The PDGF level before RT
inversely correlated with the mitral E before RT (rho =
─0.288, p = 0.022), after RT (rho =─0.416, p = 0.001)
and at three years (rho =─0.270, p = 0.033).
TGF-β1 trajectories
Trajectory analysis was performed to group the patients
by behavior of TGF-β1. Group 1 (n = 19) had signifi-
cantly higher levels of TGF-β1 before RT, after RT and
at 3 years than group 2 (n = 44), p < 0.001 for all time
points (Table 3). In group 1, there was a tendency for
TGF-β1 levels to decrease from before to after RT and
to the three-year follow-up, p = 0.066 and p = 0.080 re-
spectively. In group 2, there was a significant decrease in
the TGF-β1 level from baseline to after RT, p = 0.023,
and to the three-year follow-up, p = 0.006. The groups
were similar in baseline characteristics (Table 3), and
there were no significant differences in the proBNP
levels at the three time points between the groups.
Echocardiographic parameters by the two trajectory
groups are shown in Table 4. Baseline measurements
were similar between the two groups. The IVS at 3 years,
the PW after RT and the PW at 3 years were signifi-
cantly different between the groups, p = 0.016, p = 0.039
and p = 0.010, respectively. There was a tendency for a
difference in GLS at 3 years, p = 0.081. During RT, there
was a significant change for group 1 in IVS (p = 0.036),
PW (p = 0.030), TAPSE (p = 0.021) and scIBS (p =
0.030). For group 2 there was a significant change during
RT in TAPSE (p = 0.030) and scIBS (p = 0.007). During
the three-year follow-up, GLS and scIBS significantly
worsened from baseline in group 1, p = 0.013 and p <
0.001, respectively. In group 2, PW decreased and scIBS
increased from baseline to 3 years, p = 0.028 and p =
0.002, respectively. Radiation doses to the heart, left ven-
tricle (LV), right ventricle (RV) and the left anterior de-
scending artery (LAD) were similar between the two
trajectory groups (Additional file 3: Table S3).
To further explore the association between TGF-β1
and GLS suggested by correlation and the significant
worsening in trajectory group 1, multivariable linear re-
gression analysis was performed. In the model, TGF-β1
trajectory group 1 (β = 0.27, p = 0.013), left-sided breast
cancer (β = 0.39, p = 0.001) and the use of AI (β = 0.29,
p = 0.011) were significantly associated with a reduction
in GLS from before RT to 3 years. Additionally, there
was tendency for age to be associated (β = 0.18, p =
0.071) with worsening GLS during the three-year follow-
up. These factors explained 33% of the change in GLS.
PDGF trajectories
A trajectory analysis was also performed for PDGF.
PDGF levels were significantly higher at all time-points
Table 2 Correlations between TGF-β1, PDGF and proBNP
TGF-β1
before RT
TGF-β1
after RT
TGF-β1
3 years
Change in TGF-β1
before RT–after RT
Change in TGF-β1
before RT–3 years
Change in TGF-β1
after RT–3 years
PDGF before RT 0.667 0.222 0.132 ─0.405 ─0.480 ─0.088
PDGF after RT 0.453 0.713 0.316 0.249 ─0.141 ─0.361
PDGF 3 years 0.299 0.338 0.749 0.022 0.336 0.414
Change in PDGF before RT–after RT ─0.221 0.481 0.246 0.646 0.363 ─0.204
Change in PDGF before RT–3 years ─0.254 ─0.128 0.625 0.308 0.739 0.513
Change in PDGF after RT–3 years ─0.132 ─0.267 0.544 ─0.152 0.600 0.826
proBNP before RT 0.298 ─0.037 ─0.040 ─0.325 ─0.280 ─0.050
proBNP after RT 0.265 ─0.041 ─0.006 ─0.252 ─0.183 ─0.005
proBNP 3 years 0.293 ─0.060 ─0.061 ─0.321 ─0.297 ─0.070
Change in proBNP before RT–after RT ─0.040 ─0.016 0.054 0.101 0.150 0.075
Change in proBNP before RT–3 years 0.114 0.087 0.004 ─0.023 ─0.111 ─0.129
Change in proBNP after RT–3 years 0.212 0.018 0.004 ─0.259 ─0.232 ─0.060
TGF-β1 transforming growth factor beta 1, PDGF Platelet-derived growth factor, proBNP N-terminal pro-brain natriuretic peptide, RT Radiotherapy, Correlation
coefficients (Spearman’s rho) in bold are statistically significant (p < 0.05)
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in group 1 (n = 8) than in group 2 (n = 55), p < 0.001
(Additional file 4: Table S4) for all time-points. The groups
did not differ in baseline characteristics (Additional file 4:
Table S4). The change in PDGF was only significant in
group 2 from before to after RT, p = 0.001.
Only scIBS at 3 years was significantly higher in group
1 than group 2, p = 0.044. The elevated PDGF levels in
group 1 were not associated with more changes in echo-
cardiographic parameters, but the group 1 was too small
for a meaningful comparison (Additional file 5: Table S5).
Furthermore, radiation doses to the heart, LV, RV or
LAD were similar in the groups (Additional file 4:
Table S4).
Discussion
Elevated baseline TGF-β1 associates with
echocardiographic changes
The most important finding in our study was the associ-
ation of elevated TGF-β1 before RT with a decline in LV
systolic function, namely, impairment in GLS during the
three-year follow-up. This association was apparent in
the correlation between TGF-β1 and GLS at 3 years and
further with the trajectory analysis in which patients
were grouped into two groups according to TGF-β1 be-
havior. Group 1 had significantly higher baseline TGF-
β1 levels than group 2. At baseline, the echocardio-
graphic parameters were similar, but RT induced a
thickening of the IVS and PW during RT in group 1, but
not in group 2. These changes most likely depict RT-
induced inflammatory changes. During the three-year
follow-up, group 1 had a significant worsening of GLS
and group 2 did not. In multivariable analysis, the trajec-
tory group 1 remained a significant factor in predicting
GLS worsening during the 3 years in addition to AI use
and left-sided breast cancer, which we have reported in
earlier to affect echocardiographic parameters [12, 13].
Left-sided breast cancer associates with higher radiation
doses to the heart [19], which probably explains the
significance of the side. Radiation dose is a significant
factor determining cardiovascular risk of breast cancer
patients and dose-volume constraints are in clinical use
to decrease this risk [20]. Radiation doses were similar
between the groups, as the grouping mostly reflects a
difference in baseline TGF-β1. The worsening in GLS is
probably the most clinically significant echocardio-
graphic change, as GLS is an excellent early predictor of
major adverse cardiac events [21]. Additionally, the cor-
relation between the levels of TGF-β1 and proBNP, an
accepted marker of heart failure [22], at all three time-
points further supports the association of elevated TGF-
β1 levels and cardiovascular changes.
In previous literature, two other studies with adjuvant
external beam RT [8] and intracavitary partial breast
brachytherapy [9] reported elevated circulating baseline
TGF-β1 levels in patients who developed radiation-in-
duced fibrosis of the breast. Studies with genetic muta-
tions also support the idea that baseline TGF-β1 levels
may predispose individuals to normal tissue toxicity
Table 3 TGF-β1 levels and baseline characteristics according to two groups determined by a TGF-β1 trajectory analysis
n Group 1 n Group 2 p
TGF-β1 before RT (ng/ml) Md (IQR) 19 25.6 (22.3–28.6) 44 17.8 (15.9–19.9) < 0.001
TGF-β1 after RT (ng/ml), Md (IQR) 19 23.9 (21.3–25.2) 44 16.3 (13.7–19.1) < 0.001
TGF-β1 at 3 years (ng/ml), Md (IQR) 19 22.4 (18.8–25.8) 44 15.0 (12.1–18.8) < 0.001
Age, Md (IQR) 19 64 (58–66) 44 64 (59–68) 0.752
BMI, Md (IQR) 19 26.9 (24.8–32.3) 44 25.7 (24.1–28.7) 0.110
Left-sided BC, n (%) 19 14 (73.7) 44 36 (81.8) 0.508
AI-use, n (%) 19 6 (31.2) 44 15 (34.1) 1.000
Tamoxifen use, n (%) 19 2 (10.5) 44 4 (9.1) 1.000
ACE or ARB use, n (%) 19 5 (26.3) 44 12 (27.3) 1.000
ASA use, n (%) 19 1 (5.3) 44 4 (9.1) 1.000
Beta-blocker use, n (%) 19 4 (21.1) 44 7 (15.9) 0.721
Statin use, n (%) 19 3 (15.8) 44 10 (22.7) 0.738
CAD, n (%) 19 2 (10.5) 44 1 (2.3) 0.214
Diabetes, n (%) 17 3 (17.6) 42 2 (4.8) 0.138
Hypertension, n (%) 19 9 (47.4) 44 15 (34.1) 0.400
Hypothyroidism, n (%) 19 3 (15.8) 44 7 (15.9) 1.000
Smoking, n (%) 19 2 (10.5) 44 5 (11.4) 1.000
TGF-β1 Transforming growth factor beta 1, RT Radiotherapy, Md Median, IQR Interquartile range, BMI Body mass index, BC Breast cancer, AI Aromatase inhibitor,
ACE Angiotensin converting enzyme inhibitor, ARB Angiotensin II receptor blocker, ASA Low dose acetylsalicylic acid, CAD Coronary artery disease, Diabetes Use of
diabetes medication
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from RT. Circulating levels of TGF-β1 are, at least par-
tially, controlled genetically [3]. The TGF-β1 C-509 T
variant allele (rs1800469) is associated with elevated
levels of circulating TGF-β1 [3]. Prospective studies
present contradictory evidence of the association be-
tween TGF-β1 C-509 T variant allele and radiation-in-
duced fibrosis of the breast [4, 5]. There is some
evidence that mutations in TGF-β1 genes are linked to
cardiovascular risk. In patients receiving postoperative
RT for breast cancer, patients with the TGF-β1 29C > T
variant allele, associated with low TGF-β1 levels, had an
increased cardiovascular risk with HR 1.79. However, in
this study, there was no association between CV mortality
and radiation dose [7]. Furthermore, the role of TGF-β1 is
not clear in cardiovascular diseases. The evidence on the
role of TGF-β1 in atherosclerosis is contradictory, but
most studies suggest TGF-β1 inhibits atherosclerosis [23].
In contrast, elevated levels of TGF-β1 are associated with,
for example, hypertrophic cardiomyopathy [23].
Changes in TGF-β1 levels
Earlier, we reported that TGF-β1 and PDGF decrease
during RT [10], but this study shows that TGF-β1 re-
mains at a lower level at 3 years compared to before RT.
The decreases were small but statistically significant. In
a suggested model, RT is thought to induce a cytokine
release [2], but since we only have measurements for be-
fore and after RT, a cytokine release could have taken
place earlier during the RT course. One previous study
with intraoperative RT (IORT) for breast cancer re-
ported that IORT had no effect on the TGF-β1 levels
measured from wound fluid [24]. We found that a de-
crease in TGF-β1 during RT and the three-year follow-
up correlated with worsening LV systolic function e.g.
GLS. Additionally, the three-year change was correlated
with an increased echodensity of the myocardium, scIBS,
and LV measurements. The inverse correlations between
the change in TGF-β1 levels and proBNP levels, further
suggest that the decrease in TGF-β1 may be associated
with an increased cardiovascular risk.
PDGF levels and associations with echocardiographic
measurements
We also found associations between elevated baseline
PDGF levels and LV systolic function, e.g. worsening
GLS, and LV diastolic function, e.g. decreased mitral E.
The change in PDGF during RT also predicted impair-
ment in GLS over 3 years. The trajectory analysis did
not further support the usability of PDGF in predicting
RT-induced echocardiographic changes. Additionally,
there were no correlations between PDGF and proBNP.
Therefore, despite the strong correlation between the
two biomarkers, TGF-β1 seems to be more usable than
PDGF in predicting the cardiovascular effects of RT. To
our knowledge, no previous studies exist about the
PDGF and RT-induced toxicity in humans.
Limitations
Although we now present results with 3 years of follow-
up, the follow-up time is still short, considering that the
increased risk of cardiovascular effects of RT takes years
to manifest. Longer follow-up will show whether the
echocardiographic changes lead to clinical cardiovascular
morbidity. This may require larger studies than ours.
Additionally, the underlying cause of elevation of TGF-
β1 is not known nor do we have information on how
well other risk factors of cardiovascular diseases, such as
elevated blood pressure, diabetes, and hyperlipidemia,
are controlled in the patients. These factors could influ-
ence the results.
Conclusions
Our finding supports that elevated TGF-β1 before RT is
a risk factor for the susceptibility to normal tissue tox-
icity and is associated with RT-induced changes in echo-
cardiography, namely, impairment in GLS, a measure of
LV systolic function. An elevated TGF-β1 level is an in-
dependent risk factor for the impairment in GLS in
addition to AI use and left-sided breast cancer, which is
likely due to higher radiation doses in left-sided breast
cancer. Furthermore, a decrease in TGF-β1 during the
three-year follow-up also correlated with echocardio-
graphic changes. More studies and longer follow-up are
needed to confirm whether elevated TGF-β1 can be used
to determine which patients are at an increased risk for
radiation-induced heart disease. Further, this informa-
tion could even be useful when designing future cardio-
protective trials.
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